Additionally, metabolic adaptations in MAFLD-lean individuals, such as increased bile acid secretion and heightened farnesoid X receptor activity in response to an ‘obesogenic’ environment, might fail to prevent hepatic inflammation and fibrosis as liver disease progresses, ultimately leading to adverse long-term outcomes (Hagstrom et al., 2018). Here, NR1H4 is linked to liver disorder.